News for ALX Oncology Holdings Inc. (ALXO)

SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") ( ALXO), a clinical-stage biotechn

On May 21, 2025, UBS analyst Colin Bristow issued an update on ALX Oncology Holdings (ALXO). The report confirmed a 'Buy' rating for the stock, maintaining its

UBS has revised its price target for ALX Oncology (ALXO), bringing it down to $1 from the previous target of $1.20. Despite this adjustment, UBS maintains a Buy

**media[612714]**

UBS has revised its price target for ALX Oncology (ALXO) shares, decreasing it from $2.20 to $1.20. Despite the reduction, the firm maintains a Buy rating on th

- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenali

ALX Oncology (ALXO) has released promising findings from an ongoing Phase 1/2 trial of its lead candidate, evorpacept, in conjunction with rituximab and lenalid

**media[605889]**

ALX Oncology's lead drug, evorpacept, did not meet primary goals in key trials, impacting share price. Analysts predict substantial potential upside despi

ALX Oncology's (ALXO) Phase 2 ASPEN-03 and ASPEN-04 trials for evorpacept with KEYTRUDA® did not meet primary endpoints. Despite setbacks in head and n

ALX Oncology (ALXO) recently announced the results of its Phase 2 clinical trials, ASPEN-03 and ASPEN-04, which evaluated the combination of its CD47-blocker, e

**media[605613]**

**media[587788]**

ALX Oncology Holdings (ALXO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

PR NewswireVANCOUVER, BC, March 8, 2025 USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 8, 2025 /PRNewswire/

We recently published an article titled Micro-, Small-Cap Firms Dominate Market Rally. In this article, we are going to take a look at where ALX Oncology Holdings Inc.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (”œALX Oncology” or the ”œCompany”) ( ALXO), a clinical-stage

ALX Oncology Holdings Inc. (ALXO, Financials) saw its stock price fall 15.8% to $1.52 as of 2:32 p.m. GMT-5 on Thursday, despite announcing positive updated res